Table 2.
Dynamics of lymphocyte counts and inflammatory markers in the vitamin D3 and placebo groups before the treatment and on day 7 after the treatment1.
| Variable | Vitamin D3 (n = 52 «before»; n = 38 «after») | P value2 | Placebo (n = 54 «before»; n = 18 «after») | P value2 | P value3 | ||
|---|---|---|---|---|---|---|---|
| Before | After | Before | After | ||||
| Lymphocytes, 109/L | 0.7 (0.54–0.98) | 0.78 (0.42–1.22) | 0.01 | 0.9 (0.6–1.1) | 1.2 (0.81–1.53) | 0.73 | 0.05 |
| NK cells CD3−CD56+CD16+, % | 1.26 (0.8–2) | 9.76 (0.9–20) | 0.001 | 1.3 (0.9–2.6) | 0.92 (0.57–11) | 0.39 | 0.03 |
| NKT cells CD3+CD56+CD16+, % | 0.5 (0.3–1.3) | 2.6 (0.76–12) | 0.001 | 0.9 (0.17–2.3) | 0.45 (0.07–0.8) | 0.15 | 0.001 |
| NLR | 10.4 (7–16) | 12.5 (7–28) | 0.33 | 8.5 (5–14) | 8.3 (5–12) | 0.35 | 0.01 |
| Interleukin-6, pg/mL | 190 (97–620) | 312 (114–2156) | 0.38 | 77 (30–316) | 275 (49–4666) | 1.00 | 0.9 |
| C-reactive protein, mg/L | 194 (92–278) | 85 (13–200) | 0.002 | 125 (85–194) | 138 (62–247) | 0.76 | 0.07 |
| Procalcitonin, ng/mL | 0.54 (0.24–2) | 1.1 (0.32–1.9) | 0.02 | 0.3 (0.13–0.8) | 1.4 (0.4–12) | 0.009 | 0.32 |
1Numerical data are expressed as median (IQR); categorical data are shown as the number of cases (percentage).
2P values were calculated by Wilcoxon test, χ2 test, or Fisher’s exact test, as appropriate.
3P values were calculated by Mann–Whitney test between vitamin D3 and placebo groups on day 7.
NLR neutrophil to lymphocyte ratio.
Significant values are in bold.